CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN SERIES A NON-VOTING CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Preferred Stock Series A Non-Voting Convertible Preferred Stock	Preferred Stock Series A-1 Non-Voting Convertible Preferred Stock	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Treasury Stock	Total
Balances, Beginning at Dec. 31, 2023			$ 77	$ 65,575,167	$ (61,469,222)		$ (299,128)	$ 3,806,894
Balances, Beginning (in shares) at Dec. 31, 2023			770,317
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Share-based compensation expense				138,969				138,969
Net loss					(1,291,335)			(1,291,335)
Balances, Ending at Mar. 31, 2024			$ 77	65,714,136	(62,760,557)		(299,128)	2,654,528
Balances, Ending (in shares) at Mar. 31, 2024			770,317
Balances, Beginning at Dec. 31, 2023			$ 77	65,575,167	(61,469,222)		(299,128)	3,806,894
Balances, Beginning (in shares) at Dec. 31, 2023			770,317
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss								(2,341,168)
Balances, Ending at Jun. 30, 2024			$ 111	67,245,220	(63,810,390)		(299,128)	3,135,813
Balances, Ending (in shares) at Jun. 30, 2024			1,110,317
Balances, Beginning at Mar. 31, 2024			$ 77	65,714,136	(62,760,557)		(299,128)	2,654,528
Balances, Beginning (in shares) at Mar. 31, 2024			770,317
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Proceeds from issuance of shares, net of fees			$ 34	1,382,136				1,382,170
Proceeds from issuance of shares, net of fees (in shares)			340,000
Share-based compensation expense				148,948				148,948
Net loss					(1,049,833)			(1,049,833)
Balances, Ending at Jun. 30, 2024			$ 111	67,245,220	(63,810,390)		(299,128)	3,135,813
Balances, Ending (in shares) at Jun. 30, 2024			1,110,317
Balances, Beginning at Dec. 31, 2024	$ 74,405,362							$ 74,405,362
Balances, Beginning (in Shares) at Dec. 31, 2024	2,213.8044							2,213.8044
Increase (Decrease) in Temporary Equity [Roll Forward]
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock	$ 1,256,662
Balances, Ending at Mar. 31, 2025	$ 75,662,024
Balances, Ending (in Shares) at Mar. 31, 2025	2,213.8044
Balances, Beginning at Dec. 31, 2024			$ 133	67,856,589	(73,818,946)	$ (3,862,987)	(299,128)	$ (10,124,339)
Balances, Beginning (in shares) at Dec. 31, 2024			1,332,178
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Conversion of loan payable plus interest into Series A-1 Non-Voting Convertible Preferred Stock		$ 24,994,461						24,994,461
Conversion of loan payable plus interest into Series A-1 Non-Voting Convertible Preferred Stock (in shares)		284.2638
Proceeds from issuance of shares, net of fees			$ 58	4,252,735				4,252,793
Proceeds from issuance of shares, net of fees (in shares)			578,950
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock				(1,256,662)				(1,256,662)
Share-based compensation expense				84,474				84,474
Net loss					(10,924,952)			(10,924,952)
Foreign currency translation adjustment						61,156		61,156
Balances, Ending at Mar. 31, 2025		$ 24,994,461	$ 191	70,937,136	(84,743,898)	(3,801,831)	(299,128)	7,086,931
Balances, Ending (in shares) at Mar. 31, 2025		284.2638	1,911,128
Balances, Beginning at Dec. 31, 2024	$ 74,405,362							$ 74,405,362
Balances, Beginning (in Shares) at Dec. 31, 2024	2,213.8044							2,213.8044
Increase (Decrease) in Temporary Equity [Roll Forward]
Accrual of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock								$ (1,256,662)
Balances, Ending at Jun. 30, 2025	$ 75,662,024							$ 75,662,024
Balances, Ending (in Shares) at Jun. 30, 2025	2,269.1494							2,269.1494
Balances, Beginning at Dec. 31, 2024			$ 133	67,856,589	(73,818,946)	(3,862,987)	(299,128)	$ (10,124,339)
Balances, Beginning (in shares) at Dec. 31, 2024			1,332,178
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net loss								(14,732,305)
Foreign currency translation adjustment								3,595,698
Balances, Ending at Jun. 30, 2025		$ 24,994,461	$ 191	71,001,615	(88,551,251)	(267,289)	(299,128)	6,878,599
Balances, Ending (in shares) at Jun. 30, 2025		284.2638	1,911,128
Balances, Beginning at Mar. 31, 2025	$ 75,662,024
Balances, Beginning (in Shares) at Mar. 31, 2025	2,213.8044
Increase (Decrease) in Temporary Equity [Roll Forward]
Issuance of paid-in-kind dividends on Series A Non-Voting Convertible Preferred Stock ( in shares)	55.345
Balances, Ending at Jun. 30, 2025	$ 75,662,024							$ 75,662,024
Balances, Ending (in Shares) at Jun. 30, 2025	2,269.1494							2,269.1494
Balances, Beginning at Mar. 31, 2025		$ 24,994,461	$ 191	70,937,136	(84,743,898)	(3,801,831)	(299,128)	$ 7,086,931
Balances, Beginning (in shares) at Mar. 31, 2025		284.2638	1,911,128
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Additional fees associated with issuance of common stock				(548)				(548)
Share-based compensation expense				65,027				65,027
Net loss					(3,807,353)			(3,807,353)
Foreign currency translation adjustment						3,534,542		3,534,542
Balances, Ending at Jun. 30, 2025		$ 24,994,461	$ 191	$ 71,001,615	$ (88,551,251)	$ (267,289)	$ (299,128)	$ 6,878,599
Balances, Ending (in shares) at Jun. 30, 2025		284.2638	1,911,128

Dogwood Therapeutics, Inc. 10-Q